NO300198B1 - Farmasöytisk dideoksypurinnukleosid-preparat for oral administrering - Google Patents
Farmasöytisk dideoksypurinnukleosid-preparat for oral administrering Download PDFInfo
- Publication number
- NO300198B1 NO300198B1 NO922807A NO922807A NO300198B1 NO 300198 B1 NO300198 B1 NO 300198B1 NO 922807 A NO922807 A NO 922807A NO 922807 A NO922807 A NO 922807A NO 300198 B1 NO300198 B1 NO 300198B1
- Authority
- NO
- Norway
- Prior art keywords
- approx
- preparation
- magnesium
- ddl
- antacid
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 28
- 239000000203 mixture Substances 0.000 claims abstract description 66
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 57
- 239000003159 antacid agent Substances 0.000 claims abstract description 45
- 238000009472 formulation Methods 0.000 claims abstract description 43
- 239000003826 tablet Substances 0.000 claims abstract description 29
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 14
- SEIGJEJVIMIXIU-UHFFFAOYSA-J aluminum;sodium;carbonate;dihydroxide Chemical compound [Na+].O[Al+]O.[O-]C([O-])=O SEIGJEJVIMIXIU-UHFFFAOYSA-J 0.000 claims abstract description 6
- 229940015828 dihydroxyaluminum sodium carbonate Drugs 0.000 claims abstract description 6
- 229940069428 antacid Drugs 0.000 claims description 44
- 230000001458 anti-acid effect Effects 0.000 claims description 37
- 239000000872 buffer Substances 0.000 claims description 26
- -1 antacid magnesium compound Chemical class 0.000 claims description 23
- 239000002777 nucleoside Substances 0.000 claims description 12
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 12
- 238000011095 buffer preparation Methods 0.000 claims description 11
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 9
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 8
- 239000000347 magnesium hydroxide Substances 0.000 claims description 8
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 235000003599 food sweetener Nutrition 0.000 claims description 6
- 239000007935 oral tablet Substances 0.000 claims description 6
- 239000003765 sweetening agent Substances 0.000 claims description 6
- 108010011485 Aspartame Proteins 0.000 claims description 5
- 239000000605 aspartame Substances 0.000 claims description 5
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 5
- 229960003438 aspartame Drugs 0.000 claims description 5
- 235000010357 aspartame Nutrition 0.000 claims description 5
- 239000006185 dispersion Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 239000000395 magnesium oxide Substances 0.000 claims description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 3
- 229940042126 oral powder Drugs 0.000 claims description 3
- 229940096978 oral tablet Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 235000012239 silicon dioxide Nutrition 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 239000004135 Bone phosphate Substances 0.000 claims description 2
- 241001672694 Citrus reticulata Species 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- 235000007297 Gaultheria procumbens Nutrition 0.000 claims description 2
- 241000333569 Pyrola minor Species 0.000 claims description 2
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 claims description 2
- UOVKYUCEFPSRIJ-UHFFFAOYSA-D hexamagnesium;tetracarbonate;dihydroxide;pentahydrate Chemical compound O.O.O.O.O.[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O UOVKYUCEFPSRIJ-UHFFFAOYSA-D 0.000 claims description 2
- 239000001095 magnesium carbonate Substances 0.000 claims description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 2
- 229940031958 magnesium carbonate hydroxide Drugs 0.000 claims description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 claims description 2
- 239000004137 magnesium phosphate Substances 0.000 claims description 2
- 229960002261 magnesium phosphate Drugs 0.000 claims description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 claims description 2
- 235000010994 magnesium phosphates Nutrition 0.000 claims description 2
- 239000000391 magnesium silicate Substances 0.000 claims description 2
- 229940099273 magnesium trisilicate Drugs 0.000 claims description 2
- 229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 2
- 235000019793 magnesium trisilicate Nutrition 0.000 claims description 2
- OUHCLAKJJGMPSW-UHFFFAOYSA-L magnesium;hydrogen carbonate;hydroxide Chemical compound O.[Mg+2].[O-]C([O-])=O OUHCLAKJJGMPSW-UHFFFAOYSA-L 0.000 claims description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 3
- 229920001519 homopolymer Polymers 0.000 claims 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003974 emollient agent Substances 0.000 claims 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 29
- 239000003814 drug Substances 0.000 abstract description 29
- 239000007910 chewable tablet Substances 0.000 abstract description 16
- 239000000843 powder Substances 0.000 abstract description 12
- 239000007919 dispersible tablet Substances 0.000 abstract description 6
- 239000011777 magnesium Substances 0.000 abstract description 6
- 229910052749 magnesium Inorganic materials 0.000 abstract description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract description 3
- 230000003139 buffering effect Effects 0.000 abstract 2
- 150000003834 purine nucleoside derivatives Chemical class 0.000 abstract 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 20
- 229960002656 didanosine Drugs 0.000 description 17
- 239000000825 pharmaceutical preparation Substances 0.000 description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 9
- 235000010216 calcium carbonate Nutrition 0.000 description 9
- 229940068682 chewable tablet Drugs 0.000 description 9
- 239000007979 citrate buffer Substances 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 238000006386 neutralization reaction Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 6
- 239000007916 tablet composition Substances 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 229910052782 aluminium Inorganic materials 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 125000003835 nucleoside group Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000013256 coordination polymer Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229940100692 oral suspension Drugs 0.000 description 3
- 230000036515 potency Effects 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000005223 Alkalosis Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 230000002340 alkalosis Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- OCLZPNCLRLDXJC-NTSWFWBYSA-N 2-amino-9-[(2r,5s)-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1CC[C@@H](CO)O1 OCLZPNCLRLDXJC-NTSWFWBYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- TUOFDTDURRKFTE-UHFFFAOYSA-J [K+].O[Al+]O.[O-]C([O-])=O Chemical compound [K+].O[Al+]O.[O-]C([O-])=O TUOFDTDURRKFTE-UHFFFAOYSA-J 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- PPQREHKVAOVYBT-UHFFFAOYSA-H aluminium carbonate Inorganic materials [Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O PPQREHKVAOVYBT-UHFFFAOYSA-H 0.000 description 1
- 229940118662 aluminum carbonate Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011436 cob Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 235000019541 flavored milk drink Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940099076 maalox Drugs 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 150000002681 magnesium compounds Chemical class 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229940039506 mylanta Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/12—Magnesium silicate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73354791A | 1991-07-22 | 1991-07-22 | |
| US88220492A | 1992-05-13 | 1992-05-13 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO922807D0 NO922807D0 (no) | 1992-07-16 |
| NO922807L NO922807L (no) | 1993-01-25 |
| NO300198B1 true NO300198B1 (no) | 1997-04-28 |
Family
ID=27112590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO922807A NO300198B1 (no) | 1991-07-22 | 1992-07-16 | Farmasöytisk dideoksypurinnukleosid-preparat for oral administrering |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5880106A (de) |
| EP (1) | EP0524579B1 (de) |
| JP (1) | JP3038456B2 (de) |
| KR (1) | KR960011772B1 (de) |
| CN (1) | CN1042299C (de) |
| AT (1) | ATE163855T1 (de) |
| AU (1) | AU657337B2 (de) |
| CA (1) | CA2074215C (de) |
| DE (1) | DE69224684T2 (de) |
| DK (1) | DK0524579T3 (de) |
| ES (1) | ES2113389T3 (de) |
| FI (1) | FI105153B (de) |
| GR (1) | GR3026332T3 (de) |
| HU (3) | HU9202318D0 (de) |
| IE (1) | IE922365A1 (de) |
| IL (1) | IL102519A (de) |
| MX (1) | MX9204256A (de) |
| NO (1) | NO300198B1 (de) |
| NZ (1) | NZ243567A (de) |
| PL (1) | PL295329A1 (de) |
| RU (1) | RU2089193C1 (de) |
| TW (1) | TW211521B (de) |
| ZA (1) | ZA925484B (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122207B2 (en) * | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
| UA69413C2 (uk) * | 1998-05-22 | 2004-09-15 | Брістол-Майерс Сквібб Компані | Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції |
| IL134592A0 (en) * | 1998-06-18 | 2001-04-30 | Univ George Washington | Compositions comprising camptothecin compounds for the treatment of cancer with reduced side effects |
| UA73092C2 (uk) * | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
| US20040028772A1 (en) * | 2000-08-14 | 2004-02-12 | Carsten Andersen | Method for preparation of chewing gum with customer acceptable taste |
| US6887926B1 (en) | 2001-11-16 | 2005-05-03 | Oatey Co. | Bonding compositions for chlorinated polymers and methods of using the same |
| CN100415211C (zh) * | 2003-07-03 | 2008-09-03 | 上海现代药物制剂工程研究中心 | 抗艾滋病药去羟肌苷的肠溶微粒组合物及制备方法 |
| US20080299227A1 (en) * | 2007-05-30 | 2008-12-04 | Sunhealth Therapies, Inc. | Method for removal of HIV from the gastrointestinal tract and bile of HIV-infected subjects and for the prevention of drug failure and prevention of development of AIDS in HIV-infected subjects |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| EA201100851A1 (ru) | 2008-12-23 | 2012-04-30 | Фармассет, Инк. | Аналоги нуклеозидов |
| CL2009002206A1 (es) | 2008-12-23 | 2011-08-26 | Gilead Pharmasset Llc | Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales. |
| NZ593648A (en) | 2008-12-23 | 2013-09-27 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TWI576352B (zh) | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| BR112012024884A2 (pt) | 2010-03-31 | 2016-10-18 | Gilead Pharmasset Llc | síntese estereosseletiva de ativos contendo fósforo |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| EP2609923B1 (de) | 2010-03-31 | 2017-05-24 | Gilead Pharmasset LLC | Verfahren zur krystallisierung von (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoat |
| EP2428201A1 (de) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Orale Verabreichung von Nukleosidmonophosphaten |
| AR084044A1 (es) | 2010-11-30 | 2013-04-17 | Pharmasset Inc | Compuestos 2’-espiro-nucleosidos |
| CN102949406B (zh) * | 2011-08-31 | 2014-03-12 | 天津药物研究院 | 一种复方艾夫他滨药物组合物及其制备方法和用途 |
| AR089857A1 (es) * | 2012-02-02 | 2014-09-24 | Glaxosmithkline Llc | Comprimido antiacido para refrescar el aliento |
| ES2821528T3 (es) | 2012-11-14 | 2021-04-26 | Grace W R & Co | Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado |
| CN104069126A (zh) * | 2014-07-02 | 2014-10-01 | 浙江康乐药业股份有限公司 | 一种治疗胃酸过多的药物及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260596A (en) * | 1979-08-13 | 1981-04-07 | Bristol-Myers Company | Edible unit dosage form consisting of outer mannitol shell and inner liquid or gel center and method for manufacturing the same |
| US4339428A (en) * | 1980-08-18 | 1982-07-13 | Bristol-Myers Company | Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component |
| CA1239349A (en) * | 1983-10-10 | 1988-07-19 | Eberhard F. Gottwald | Pharmaceutical composition containing cimetidine |
| JPS62501712A (ja) * | 1985-08-26 | 1987-07-09 | アメリカ合衆国 | ２′、３′―ジデオキシイノシン、２′，３′―ジデオキシグアノシンまたは２′，３′―ジデオキシアデノシンを含有する抗ｈｔｌｖ―３／ｌａｖ剤 |
| GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| CH674148A5 (de) * | 1986-06-24 | 1990-05-15 | Racz Istvan | |
| WO1988002629A1 (en) * | 1986-10-16 | 1988-04-21 | American Health Products Corporation | 2',3'-didesoxyadenosine composition |
| US4935243A (en) * | 1988-12-19 | 1990-06-19 | Pharmacaps, Inc. | Chewable, edible soft gelatin capsule |
| US5026687A (en) * | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
-
1992
- 1992-07-15 HU HU9202318A patent/HU9202318D0/hu unknown
- 1992-07-15 NZ NZ243567A patent/NZ243567A/en unknown
- 1992-07-16 JP JP4231248A patent/JP3038456B2/ja not_active Expired - Lifetime
- 1992-07-16 IL IL10251992A patent/IL102519A/en not_active IP Right Cessation
- 1992-07-16 TW TW081105639A patent/TW211521B/zh not_active IP Right Cessation
- 1992-07-16 NO NO922807A patent/NO300198B1/no not_active IP Right Cessation
- 1992-07-17 PL PL29532992A patent/PL295329A1/xx unknown
- 1992-07-20 AU AU20396/92A patent/AU657337B2/en not_active Expired
- 1992-07-20 AT AT92112371T patent/ATE163855T1/de active
- 1992-07-20 EP EP92112371A patent/EP0524579B1/de not_active Expired - Lifetime
- 1992-07-20 FI FI923308A patent/FI105153B/fi not_active IP Right Cessation
- 1992-07-20 ES ES92112371T patent/ES2113389T3/es not_active Expired - Lifetime
- 1992-07-20 DE DE69224684T patent/DE69224684T2/de not_active Expired - Lifetime
- 1992-07-20 CA CA002074215A patent/CA2074215C/en not_active Expired - Fee Related
- 1992-07-20 DK DK92112371.7T patent/DK0524579T3/da active
- 1992-07-21 IE IE236592A patent/IE922365A1/en not_active IP Right Cessation
- 1992-07-21 HU HU9202375A patent/HU220612B1/hu unknown
- 1992-07-21 RU SU925052174A patent/RU2089193C1/ru active
- 1992-07-21 CN CN92108657A patent/CN1042299C/zh not_active Expired - Lifetime
- 1992-07-21 ZA ZA925484A patent/ZA925484B/xx unknown
- 1992-07-21 MX MX9204256A patent/MX9204256A/es unknown
- 1992-07-21 KR KR1019920012989A patent/KR960011772B1/ko not_active IP Right Cessation
-
1995
- 1995-06-20 HU HU95P/P00275P patent/HU211285A9/hu unknown
-
1997
- 1997-10-02 US US08/942,660 patent/US5880106A/en not_active Expired - Lifetime
-
1998
- 1998-03-12 GR GR970402511T patent/GR3026332T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO300198B1 (no) | Farmasöytisk dideoksypurinnukleosid-preparat for oral administrering | |
| EP0679400B1 (de) | Orale Verabreichungsformen von Azithromycin zur Vermeidung von Interaktionen mit der Nahrung | |
| CA2019863C (en) | Aqueous pharmaceutical suspension for substantially water insoluble pharmaceutical actives | |
| RU2176507C2 (ru) | Пероральные жидкие композиции, содержащие алендронат | |
| EA001878B1 (ru) | Способ лечения бактериальных инфекций у детей | |
| AU723357B2 (en) | Liquid alendronate formulations | |
| US20030108605A1 (en) | Mineral supplement | |
| US11058138B2 (en) | Composition for calcium supplementation | |
| EA042006B1 (ru) | Композиция в качестве добавки кальция | |
| WO2018204040A1 (en) | Oral liquid compositions of valsartan | |
| WO1999004788A1 (en) | Aqueous compositions comprising ranitidine and lcmt sucrose | |
| AU6315799A (en) | Method of administering azithromycin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |